公司資料
Praxis Precision Medicines 股價、新聞與催化劑
- 股票代碼:
- PRAX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
375.94 USD (+3.12%)
收盤價
最後更新: 2026年8月21日
7.19B USD
市值
股價為何變動
As of Aug 21, 2026, PRAX closed up 3.12% at $375.94. No new same-company headline was identified in the current news window.
公司概覽
Precision Neuroscience
Praxis Precision Medicines develops therapies for genetically and physiologically defined disorders of neuronal excitation. Its pipeline spans movement disorders and developmental epilepsies.
Ulixacaltamide
Ulixacaltamide is a small-molecule T-type calcium-channel modulator under FDA review for essential tremor.
Relutrigine
Relutrigine is under Priority Review for SCN2A- and SCN8A-related developmental and epileptic encephalopathies.
Vormatrigine
Vormatrigine is an oral precision medicine being evaluated in the POWER1 study for focal-onset seizures.
Elsunersen
Elsunersen is an antisense oligonucleotide targeting the underlying biology of SCN2A-related developmental and epileptic encephalopathy.
未來催化劑
- Topline POWER1 results for vormatrigine in the second quarter of 2026.
- PDUFA target date for relutrigine on September 27, 2026.
- Topline EMERALD results for relutrigine in broad developmental and epileptic encephalopathies in the fourth quarter of 2026.
- PDUFA target date for ulixacaltamide on January 29, 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。